Center/Research Area Affiliations
Dr. Miller’s clinical and research interests focus on retinal disorders, including age related macular degeneration (AMD), diabetic eye disease, and macular telangiectasia (MacTel). She and her colleagues at Mass. Eye and Ear pioneered the development of photodynamic therapy (PDT) using verteporfin (Visudyne®), the first pharmacologic therapy for AMD. Dr. Miller also identified the role of vascular endothelial growth factor (VEGF) in ocular neovascularization, forming the scientific basis of current antiangiogenic therapies for intraocular vascular diseases (including neovascular AMD and diabetic eye disease). Dr. Miller continues investigations to elucidate the pathophysiology of vision loss and improve therapies for retinal diseases.
Neuroprotective therapies for retinal disease: Dr. Miller studies the mechanisms of photoreceptor and retinal pigment epithelium (RPE) cell death with the goal of developing effective combination neuroprotective therapies.
Genetics of AMD: In collaboration with Dr. Margaret DeAngelis of University of Utah, Dr. Miller is identifying novel loci associated with AMD and genetic differences in AMD subtypes using sibling-correlation and genome-wide association studies.
Anti-inflammatory interventions for AMD: A co-investigator in the Age-Related Eye Disease Study 2 (AREDS2), Dr. Miller studied the effects of dietary constituents in preventing AMD progression. In the laboratory, she examines the anti-inflammatory and antiangiogenic effects of fatty acid metabolites in animal models of AMD.
The MacTel Project: Dr. Miller is an investigator in a collaborative research effort to identify the causes and appropriate treatments for this idiopathic condition.
1. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep; 145 (3) :574-84. PubMed PMID:7521577; PubMed Central PMCID: PMC1890317.
2. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte TJ, Haimovici R, Gragoudas ES. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995 Jun; 113 (6) :810-8. PubMed PMID:7540388.
3. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep;117(9):1161-73. Erratum in: Arch Ophthalmol 2000 Apr;118(4):488. PubMed PMID: 10496388.
4. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar; 120 (3) :338-46. PubMed PMID:11879138.
5. Murakami Y, Matsumoto H, Roh M, Suzuki J, Hisatomi T, Ikeda Y, Miller JW, Vavvas DG. Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14598-603. doi: 10.1073/pnas.1206937109. Epub 2012 Aug 20. PubMed PMID: 22908283; PubMed Central PMCID: PMC3437885
View a complete list of publications on pubmed.gov »
View publications on Google Scholar »